NEW YORK (TheStreet) -- Shares of Achillion Pharmaceuticals (ACHN) continued to climb, up 7.07% to $13.36, in late morning trading Wednesday after the company reported encouraging interim results from a Phase II study of its hepatitis C drug ACH-3102.
The study is testing the efficacy, safety and tolerability of ACH-3102 administered over eight weeks in combination with Gilead Sciences' (GILD) drug Sovaldi in patients infected with the hepatitis C virus. Data showed that all 12 patients enrolled in the trial achieved sustained viral response 12 weeks after the eight weeks of treatment, which was the primary objective of the trial.
Achillion also announced it saw no on-treatment viral breakthrough or post-treatment viral relapse during the study.
The company made the announcement at the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting 2014, in Boston over the weekend.ACHN data by YCharts